Filing Flows › Comparisons › CRBU vs OTLK
Caribou Biosciences vs Outlook Therapeutics: CRBU and OTLK compared
Caribou Biosciences is the larger company: $1.6M of revenue in its latest quarter (Q3 2026) against $1.5M for Outlook Therapeutics (Q3 FY25).
Where the money goes: CRBU and OTLK
Caribou Biosciences (CRBU) · Q3 2026
Caribou Biosciences, Q3 2026: revenue $1.6M (-27% year over year), net loss $26.6M, operating cash flow −$22.5M. The chart follows the revenue to costs, profit and cash.
Outlook Therapeutics (OTLK) · Q3 FY25
Outlook Therapeutics, Q3 FY25: revenue $1.5M, net loss $20.2M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
| Caribou Biosciences (CRBU) | Outlook Therapeutics (OTLK) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 FY25 |
| Revenue | $1.6M | $1.5M |
| Revenue growth, Y/Y | -27% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$26.6M | −$20.2M |
| Operating cash flow | −$22.5M | −$11.9M |
Questions
Which is bigger, Caribou Biosciences or Outlook Therapeutics?
Caribou Biosciences is the larger company: $1.6M of revenue in its latest quarter (Q3 2026) against $1.5M for Outlook Therapeutics (Q3 FY25).
More: Caribou Biosciences earnings · how Caribou Biosciences makes money · Outlook Therapeutics earnings · how Outlook Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 14, 2025). Fiscal quarters can end on different dates. Not investment advice.